CBD vs. CBDA: What’s the Difference?
April 16th, 2018
The cannabis industry is fraught with acronyms – such as THC to CBD – and technical vocabulary – such as phytocannabinoids. While these terms may be difficult to understand, it’s important for consumers and physicians to know about them to make the best decisions.
CBD vs. CBDA
Cannabidiolic acid, abbreviated CBDa, is one of the primary cannabinoids produced on the stems, leaves and flowers of some varieties of cannabis plants. In most cannabis varieties, THCa is the dominate cannabinoid. Only certain strains, like Cannatonic, AC/DC, Sour Tsunami and Harlequin, are high in CBDa. Hemp can also be a viable source of CBDa.
It is not until CBDa goes through the process of decarboxylation that the “a”, which stands for acid, disappears and the new compound can be called CBD, or activated CBD.
Decarboxylation is the process by which carbon dioxide and hydrogen are removed from CBDa, transforming it into CBD. This reaction can occur naturally as the plant ages from exposure to light and heat, but is more often accelerated by heating cannabis when processing or smoking high CBD cannabis varieties. Due to their similar chemical structure, CBDa and CBD have similar therapeutic effects, but there are some differences between the two molecules. The biggest difference between the two is the amount of research conducted on each cannabinoid.
Roles in the Body
Both compounds are similar in that they activate the endocannabinoid system, but far less is known about CBDa’s roll than CBD.
The endocannabinoid system is a group of cells in the body that promote balance or homeostasis. Although CBD and other cannabinoids were discovered in 1963 by Israeli researcher Dr. Ralph Mechoulam, it wasn’t until the 1990’s that scientists learned how cannabinoids worked in the body. When functioning properly the endocannabinoid system helps regulate digestion, mood, sleep, immune function, memory, pain, fertility and other key bodily functions. Both CBDa and CBD interact with the endocannabinoid system when treating many conditions, such as, Parkinson’s Disease, Alzheimer’s, Rheumatoid Arthritis, Diabetes, MS, Epilepsy, and inflammatory conditions like Hepatitis C.
Despite being largely ignored up until recently, some studies have shown CBDa to have some anti-tumoral effects similar to its chemical cousin CBD.
In a study published in the Journal of Natural Medicines in 2012, Shuso Takeda of Hokuriku University in Japan found CBDa inhibited the growth of an aggressive form of breast cancer cells by suppressing a proto-oncogene called c-fos. The study found CBDa inhibited the growth of MDA-MB-231, a particular aggressive form of breast cancer. Scientists say more research is needed to discover the exact mechanisms responsible for the promising result. Unlike CBDa where there is little research into its ability to fight cancer, numerous studies have demonstrated CBD to be a powerful anti-cancer agent.
A promising avenue into CBD’s roll in fighting cancer looks at how CBD promotes apoptosis. Apoptosis is essentially the process of a cell self destructing. When apoptosis does not occur, cells divide out of control resulting in cancer. Several studies have shown CBD promotes apoptosis through a variety of pathways in the body. An Italian study found that a group of molecules called reactive oxygen species slowed the growth of cancer by limiting the amount of oxygen absorbed by the out of control cells. An Israeli study showed that CBD induced apoptosis by reducing inflammation in malignant brain tumors. There is also a wealth of research into CBD’s efficacy in treating many other conditions.
Another difference between CBDa and CBD is how they are consumed. Because CBDa is only found on raw cannabis flowers and leaves, CBDa is often ingested through juicing high CBD cannabis. Juicing raw cannabis is a popular method of ingesting medical cannabis. Patients often mix fruit with the cannabis to reduce bitterness, and because cannabis is a great source for phytonutrients and fiber, cannabis juice can go with almost any diet. Raw high CBD cannabis can be used in salads or other uncooked meals to deliver CBDa to a patient’s endocannabinoid system. Live resins, tinctures and nonactivated full plant extracts are other viable sources of CBDa. CBD is only available after decarboxylation occurs, so cannabis must be heated or burned to access the healing properties of CBD. Activated tinctures, lotions and nonactivated cannabis flower and extracts are popular CBD consumption methods.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Media Group (CannabisFN), owned and operated by CFN Enterprises Inc. (OTCQB: CNFN), is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.